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*To the Editor:*

The ongoing pandemic with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and resultant coronavirus disease 2019 (COVID‐19) is resulting in high mortality and morbidity worldwide.[1](#ajh25853-bib-0001){ref-type="ref"}, [2](#ajh25853-bib-0002){ref-type="ref"} While the exact impact of SARS‐CoV‐2 in cancer patients remains to be defined, early reports, especially from China, suggest an increased mortality in those older than 60 years, those with pulmonary compromise or hematological malignancies.[^3^](#ajh25853-bib-0003){ref-type="ref"} The virus SARS‐CoV‐2 uses the angiotensin converting enzymes‐related carboxypeptidase (ACE2) receptor to gain entry into cells, with these receptors widely expressed in the cardiopulmonary system, monocytes and monocyte‐derived macrophages.[^4^](#ajh25853-bib-0004){ref-type="ref"} Monocytes and macrophages frequently interact with ACE2‐expressing cells in various tissues, and ACE2 is also expressed by cells of the bone marrow (BM) niche, where it associates with the granulocyte‐colony stimulating factor (G‐CSF) receptor to negatively regulate hematopoietic progenitor cells mobilization (supplemental material for complete reference list in [Data S1](#ajh25853-supitem-0001){ref-type="supplementary-material"}).

The cytokine profile of patients with COVID‐19 resembles that of patients with secondary hemophagocytic lymphohistiocytosis (HLH), with the excess production of interleukin 2 (IL‐2), IL‐6, G‐CSF, interferon gamma inducing protein 10, monocyte chemoattractant protein‐1 and tumor necrosis factor (TNF) alpha, among others.[5](#ajh25853-bib-0005){ref-type="ref"}, [6](#ajh25853-bib-0006){ref-type="ref"} Severe manifestations of SARS‐CoV‐2 are largely cytokine mediated and include cytokine release syndrome (CRS), respiratory failure secondary to acute respiratory distress syndrome (ARDS), and multiorgan dysfunction syndrome (MODS) (Figure [S1](#ajh25853-supitem-0002){ref-type="supplementary-material"}).[1](#ajh25853-bib-0001){ref-type="ref"}, [2](#ajh25853-bib-0002){ref-type="ref"}, [5](#ajh25853-bib-0005){ref-type="ref"} Note, IL‐6 is a prominent secreted cytokine and plays a critical role in the inflammatory cascade seen.[^6^](#ajh25853-bib-0006){ref-type="ref"} This has led to the use of IL‐6 and IL‐6 receptor (IL‐6‐R)‐directed monoclonal antibodies such as siltuximab (IL‐6) and tocilizumab/sarilumab (IL‐6‐R) in the management of CRS and ARDS in patients with COVID‐19.

The 2016 iteration of the World Health rganization (WHO) classification of myeloid neoplasms identifies four distinct sub‐types of adult onset myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN), namely chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia, *BCR/ABL‐*negative (aCML), MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T), and MDS/MPN, unclassifiable (MDS/MPN‐U).[^7^](#ajh25853-bib-0007){ref-type="ref"} Among these, proliferative variants of CMML, MDS/MPN‐U and aCML tend to have persistent leukocytosis along with circulating immature myeloid cells.[^8^](#ajh25853-bib-0008){ref-type="ref"} Proliferative CMML in particular has a proinflammatory phenotype with elevated serum levels of cytokines including IL‐6, TNF‐alpha, monocyte colony stimulating factor (M‐CSF) and IL‐1RA[^9^](#ajh25853-bib-0009){ref-type="ref"}; with CMML cells demonstrating an intrinsic hypersensitivity to GM‐CSF that is more prominent in RAS‐mutant samples.[^10^](#ajh25853-bib-0010){ref-type="ref"} Case series have described exaggerated leukemoid reactions, CRS, ARDS and MODS in CMML patients who have undergone surgery, or in response to infections/inflammation; given the abundance of ACE2 receptors experessed on monocytes and macrophages, we hypothesize that these patients are particularly susceptible to the cytokine‐related complications of SARS‐CoV‐2.[^11^](#ajh25853-bib-0011){ref-type="ref"}

We describe a 69‐year‐old man with symptomatic (constitutional symptoms), proliferative, *ASXL1, NRAS, TET2* mutated‐ CMML‐0 with a normal karyotype, who had a stable white blood cell count (WBC) of \~35 × 10^9^/L for 6 months, regulated on hydroxyurea. A donor search for allogenic hematopoietic cell transplant had been initiated. Further dose increments in hydroxyurea to try to better control his leukocytosis were not tolerated, due to anemia and thrombocytopenia. The patient was admitted with high grade fever and hypoxic respiratory failure to his local hospital. His WBC on admission was 90 × 10^9^/L with neutrophilic series left‐shift and he went on to develop ARDS and MODS, necessitating assisted ventilation. He was diagnosed with SARS‐CoV‐2 and died prior to the administration of anti‐cytokine directed therapies.

Given the paucity of evidence for the management of hematological malignancies during this pandemic and the proinflammatory milieu of proliferative MDS/MPN overlap neoplasms, we formed an ad hoc expert panel to help draft consensus emergency recommendations for the management of COVID‐19 in these patients. The committee also reviewed available cytokine‐directed clinical trials for SARS‐CoV‐2 and summarized details of therapies of particular interest to patients with proliferative MDS/MPN‐overlap neoplasms (Table [1](#ajh25853-tbl-0001){ref-type="table"}).

###### 

Cytokine signaling‐associated clinical trials for COVID patients

  NCT number                                                                       Drug name                                                                    Mechanism of action                                                      Phase   Enroll \#                   Arms                                                                     Dosage                                                                                                  Location                                                 Recruitment status
  -------------------------------------------------------------------------------- ---------------------------------------------------------------------------- ------------------------------------------------------------------------ ------- --------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------- -------------------------------------------------------- -----------------------------------------------------------------
  NCT04322773                                                                      Tocilizumab vs. Sarilumab                                                    IL‐64 antagonists                                                        2       200                         Tocilizumab                                                              Single Dose 400 mg (IV)                                                                                 Denmark                                                  Yes
  Tocilizumab                                                                      Single Dose 2 × 162 mg (sc)                                                                                                                                                                                                                                                                                                                                                                                                         
  Sarilumab                                                                        Single Dose 1 × 200 mg (sc)                                                                                                                                                                                                                                                                                                                                                                                                         
  NCT04324073                                                                      Sarilumab                                                                    IL‐6R antagonist                                                         2,3     240                         Sarilumab                                                                Single Dose 1 × 400 mg (IV)                                                                             France                                                   Yes
  NCT04327388                                                                      Sarilumab                                                                    IL‐6R antagonist                                                         2,3     300                         Sarilumab                                                                Single Dose 1 concentration (IV)                                                                        Canada, France, Italy, Spain                             Yes
  Sarilumab                                                                        Single Dose 2 concentration (IV)                                                                                                                                                                                                                                                                                                                                                                                                    
  NCT04341870                                                                      Sarilumab                                                                    IL‐6R antagonist                                                         2,3     60                          Sarilumab in combo with ([^a^](#ajh25853-note-0002){ref-type="fn"}):     Single Dose 400 mg (IV) on D1                                                                           France                                                   Not open yet
  [^a^](#ajh25853-note-0002){ref-type="fn"}Azithromycin                            Oral, 500 mg on D1, 250 mg D2‐D5                                                                                                                                                                                                                                                                                                                                                                                                    
  [^a^](#ajh25853-note-0002){ref-type="fn"}Hydroxychloroquine                      Oral, 600 mg QD (200 mg TID) on D1‐D10                                                                                                                                                                                                                                                                                                                                                                                              
  Sarilumab alone                                                                  Single Dose 400 mg IV                                                                                                                                                                                                                                                                                                                                                                                                               
  NCT04315298                                                                      Sarilumab                                                                    IL‐6R antagonist                                                         2,3     400                         Sarilumab                                                                Single Dose (IV) low dose                                                                               US                                                       Yes
  Sarilumab                                                                        Single Dose (IV) high dose                                                                                                                                                                                                                                                                                                                                                                                                          
  Placebo                                                                          Single Dose (IV) to match Sarilumab                                                                                                                                                                                                                                                                                                                                                                                                 
  NCT04329650                                                                      Siltuximab                                                                   IL‐6 antagonist                                                          2       100                         Siltuximab                                                               Single Dose (IV) 11 mg/Kg                                                                               Spain                                                    Not open yet
  Methylprednisolone                                                               250 mg/24 h (IV) × 3 d followed by 30 mg/24 h × 3 d                                                                                                                                                                                                                                                                                                                                                                                 
  NCT04331795                                                                      Tocilizumab                                                                  IL‐6R antagonist                                                         2       50                          Tocilizumab (with risk factors)                                          Single Dose 200 mg (IV)‐ 2nd dose if needed                                                             US                                                       Yes
  Tocilizumab (without risk factors)                                               Single Dose 80 mg (IV)‐ 2nd dose if needed                                                                                                                                                                                                                                                                                                                                                                                          
  NCT04315480                                                                      Tocilizumab                                                                  IL‐6R antagonist                                                         2       38                          Tocilizumab                                                              Single Dose (IV) 8 mg/kg                                                                                Italy                                                    Active, not recruiting
  NCT04335071                                                                      Tocilizumab                                                                  IL‐6R antagonist                                                         2       100                         Tocilizumab                                                              Single Dose (IV) 8 mg/kg                                                                                Switzerland                                              Not open yet
                                                                                                                                                                                                                                                                                                                                                      Placebo                                                                                                 Single Dose (IV) 100 mL of NaCl 0.9%                     
  NCT04320615                                                                      Tocilizumab                                                                  IL‐6R antagonist                                                         3       330                         Tocilizumab                                                              Single Dose by IV                                                                                       US, Canada, Denmark, France, Germany, Italy, UK, Spain   Yes
  Placebo                                                                          Single Dose by IV                                                                                                                                                                                                                                                                                                                                                                                                                   
  NCT04317092                                                                      Tocilizumab                                                                  IL‐6R antagonist                                                         2       400                         Tocilizumab                                                              Single Dose 8 mg/kg (IV)                                                                                Italy                                                    Yes
  NCT04332094                                                                      Tocilizumab                                                                  IL‐6R antagonist                                                         2       276                         Tocilizumab in combo with ([^a^](#ajh25853-note-0002){ref-type="fn"}):   Two Doses on Day 1: 162 mg (sc) 12 h apart                                                              Spain                                                    Yes
  [^a^](#ajh25853-note-0002){ref-type="fn"}Azithromycin                            Oral, 500 mg on D1‐D3                                                                                                                                                                                                                                                                                                                                                                                                               
  [^a^](#ajh25853-note-0002){ref-type="fn"}Hydroxychloroquine                      Oral, 400 mg/12 h D1,200 mg/ 12 h for D2‐D6                                                                                                                                                                                                                                                                                                                                                                                         
  Azithromycin with ([^a^](#ajh25853-note-0002){ref-type="fn"}):                   Oral, 500 mg on D1‐D3                                                                                                                                                                                                                                                                                                                                                                                                               
  [^a^](#ajh25853-note-0002){ref-type="fn"}Hydroxychloroquine                      Oral, 400 mg/12 h D1, 200 mg/12 h for D2‐D6                                                                                                                                                                                                                                                                                                                                                                                         
  NCT04335305                                                                      Tocilizumab with Pembrolizumab                                               IL‐6R antagonist (Toc); Immune check point block (Pem)                   2       24                          Tocilizumab with ([^a^](#ajh25853-note-0002){ref-type="fn"}):            Single Dose 8 mg/kg (IV)                                                                                                                                         Not open yet
  [^a^](#ajh25853-note-0002){ref-type="fn"}Pembrolizumab                           Single Dose 200 mg (IV)                                                                                                                                                                                                                                                                                                                                                                                                             
  NCT04339712                                                                      Anakinra vs. Tocilizumab                                                     IL‐1R antagonist (Ana)                                                   2       20                          Tocilizumab                                                              In case of immune dysregulation: single dose 8 mg/kg (IV)                                               Greece                                                   Not open yet
  IL‐6R antagonist (Toc)                                                           Anakinra                                                                     Incase of MAS: 200 mg × 3 daily for 7 d (IV)                                                                                                                                                                                                                                                                                                           
  NCT04330638                                                                      Anakinra, Anakinra with Siltuximab, Tocilizumab, Tocilizumab with Anakinra   IL‐6 antagonist (Sil); IL‐1R antagonist (Ana); IL‐6R antagonist (Toc);   3       342                         Anakinra                                                                 Daily 100 mg (sc) for 28 d                                                                              Belgium                                                  Yes
  Siltuximab                                                                       Single Dose 11 mg/kg (IV)                                                                                                                                                                                                                                                                                                                                                                                                           
  Anakinra with ([^a^](#ajh25853-note-0002){ref-type="fn"}):                       Daily 100 mg (sc) for 28 d (or until discharge)                                                                                                                                                                                                                                                                                                                                                                                     
  [^a^](#ajh25853-note-0002){ref-type="fn"}Siltuximab                              Single Dose 11 mg/kg (IV)                                                                                                                                                                                                                                                                                                                                                                                                           
  Tocilizumab                                                                      Single Dose 8 mg/kg (IV)                                                                                                                                                                                                                                                                                                                                                                                                            
  Anakinra with ([^a^](#ajh25853-note-0002){ref-type="fn"}):                       Daily 100 mg (sc) for 28 d                                                                                                                                                                                                                                                                                                                                                                                                          
  [^a^](#ajh25853-note-0002){ref-type="fn"}Tocilizumab                             Single Dose 8 mg/kg (IV)                                                                                                                                                                                                                                                                                                                                                                                                            
  NCT04341584                                                                      Anakinra                                                                     IL‐1R antagonist                                                         2       240                         Anakinra                                                                 2 × 200 mg (IV) on D1‐D3, 2 × 100 mg (IV) on D4, 1 × 100 mg (IV) on D5                                  France                                                   Not open yet
  NCT04324021                                                                      Emapalumab or Anakinra                                                       IFN‐γ inhibitor (Ema); IL‐1R antagonist (Ana)                            2,3     54                          Emapalumab                                                               D1: 6 mg/kg (IV), D4, D7, D10, D13 3 mg/kg (IV)                                                         Italy                                                    Yes
  Anakinra                                                                         400 mg/kg (V) 4 × daily for 15 d                                                                                                                                                                                                                                                                                                                                                                                                    
  NCT04337216                                                                      Mavrilimumab                                                                 GM‐CSFR α monoclonal                                                     2       10                          Mavrilimumab                                                             Single Dose (IV)                                                                                        US                                                       Not open yet
  NCT04326920                                                                      Sargramostim                                                                 Recombinant GM‐CSF                                                       4       80                          Sargramostim                                                             Inhalation via nebulizer (125μg) for 5 d ‐continue with IV if patient requires mechanical ventilation   Belgium                                                  Yes
  NCT04331899                                                                      Peginterferon Lambda‐1 alpha                                                 IFN‐α mimetic                                                            2       120                         Peginterferon Lambda‐1 alpha                                             Single Dose (sc) 180μg                                                                                  US                                                       Not open yet
  NCT04320238                                                                      rHu interferon α‐1b with or without thymosin alpha 1                         rHu IFN‐α1b Immune modulator(Thy)                                        3       2944                        rHu IFN‐α1b                                                              Nasal drops: 2‐3 per nostril × 4 times a day                                                            China                                                    Yes
  rHu IFN‐α1b with ([^a^](#ajh25853-note-0002){ref-type="fn"}): thymosin alpha 1   Nasal drops: 2‐3 per nostril × 4 times a day sc 1 × per week                                                                                                                                                                                                                                                                                                                                                                        
  NCT04280588                                                                      Fingolimod                                                                   Sphingosine‐1‐phosphate receptor modulator                               2       50                          Fingolimod                                                               Oral 0.5 mg daily × 3 d                                                                                 China                                                    Yes
  NCT04275245                                                                      Meplazumab                                                                   humanized anti‐CD147 Ab                                                  2       20                          Meplazumab                                                               10 mg (IV) × 2 d, once per day                                                                          China                                                    Yes
  NCT04268537                                                                      PD‐1 blocking Ab                                                             Immune check point block                                                 2       120                         PD‐1 blocking Ab                                                         Single Dose 200 mg (IV)                                                                                 China                                                    Not open yet
  Thymosin                                                                         1.6 mg sc qd, × 5 d                                                                                                                                                                                                                                                                                                                                                                                                                 
  NCT04317040                                                                      CD24Fc                                                                       Inflammatory cytokine inhibitor                                          3       230                         CD24Fc                                                                   Single Dose 480 mg (IV)                                                                                 US                                                       Yes
  NCT04333472                                                                      Piclidenoson                                                                 Inflammatory cytokine inhibitor                                          2       40                          Piclidenoson                                                             Oral, 2 mg every 12 hs for up to 21 d                                                                   Israel                                                   Not open yet
  NCT04338802                                                                      Nintedanib                                                                   Tyrosine kinase inhibitor                                                2       96                          Nintedanib                                                               Oral, 150 mg 2 × daily for 8 weeks                                                                      China                                                    Not open yet
  NCT04340232                                                                      Baricitinib                                                                  JAK inhibitor                                                            2,3     80                          Baricitinib                                                              Oral, 2 mg once daily for 14 d                                                                          US                                                       Not open yet
  NCT04320277                                                                      Baricitinib in combo with Ritonavir                                          JAK inhibitor (Bar) anti‐viral (Rit)                                     3       60                          Baricitinib (mild cases)                                                 Oral, 4 mg once daily × 2 weeks; Ritonavir 600                                                          Italy                                                    Yes
  Baricitinib (moderate cases)                                                     Oral, 4 mg once daily × 2 weeks; Ritonavir 600                                                                                                                                                                                                                                                                                                                                                                                      
  NCT04331665                                                                      Ruxolitinib                                                                  JAK inhibitor                                                            NA      64                          Ruxolitinib                                                              Oral, 10 mg twice daily D1‐D14, 5 mg twice daily D15‐D16, 5 mg once daily on D17                        Canada                                                   Not open yet
  NCT04338958                                                                      Ruxolitinib                                                                  JAK inhibitor                                                            2       200                         Ruxolitinib                                                              Oral, 2 × 10 mg per day with defined response adapted dose escalation up to 2 × 20 mg for 7 d           Germany                                                  Not open yet
  NCT04334044                                                                      Ruxolitinib                                                                  JAK inhibitor                                                            1,2     20                          Ruxolitinib                                                              Oral 2 × 10 mg per day for 14 d                                                                         Mexico                                                   Not open yet
  NCT04332042                                                                      Tofacitinib                                                                  JAK inhibitor                                                            2       50                          Tofacitinib                                                              Oral, 10 mg twice daily for 14 d                                                                        ITaly                                                    Not open yet
  NCT04321993                                                                      Baricitinib                                                                  JAK inhibitor (Bar)                                                      2       1000                        Baricitinib                                                              Oral, 2 mg once a day for 10 d                                                                          Canada                                                   Not open yet
  Sarilumab                                                                        IL‐6R antagonist (Sar)                                                                                                                                        Sarilumab                   Single Dose 200 mg (sc)                                                                                                                                                                                                                   
  Hydroxychoroquine sulfate                                                        Inflammatory cytokine inhibitor (Hyd)                                                                                                                         Hydroxychoroquine sulfate   Oral, 2 × 200 mg daily for 10 d                                                                                                                                                                                                           
  Lopinavir/ritnavir                                                               Protease inhibitor (Lop)                                                                                                                                      Lopinavir/Ritnavir          Oral, 2 × 200 mg/50 mg daily for 10 d                                                                                                                                                                                                     
  NCT04341675                                                                      Sirolimus                                                                    mTOR inhibitor                                                                                               Sirolimus                                                                Oral, 6 mg once on D1, 2 mg once a day D3‐D13                                                           US                                                       Not open yet
  FDA approved compassionate use                                                   Lenzilumab                                                                   anti‐GM‐CSF antibody                                                     Pre‐3                               Approved Apr 2, 2020                                                     Sponsor: Humanigen, Inc.                                                                                US                                                       https://apnews.com/ACCESS WIRE/738d3526740dee777dacee2b6b8a836f

Abbreviations: Terminology Key: NCT, national clinical trial; IV, intravenously; sc, subcutaneous injection; IL‐6, interleukin‐6; IL‐6R, interleukin‐6 receptor; IFN‐γ, interferon gamma; GM‐CSFR α, granulocyte‐macrophage colony‐stimulating factor receptor alpha; rHu, recombinant human; IFN‐α1b, interferon alpha 1b; CD147, cluster of differentiation 147; Ab, antibody; JAK, janus kinase; D1, Day 1; NaCl, sodium chloride; mg/kg, milligram per kilogram; MAS); μg, microgram; qd, once a day; bid, twice a day.

All trials were identified from https://www.clinicaltrials.gov using filter criteria: COVID, 2019‐nCOV, SARS‐CoV‐2.

Permissive leukocytosis in these pateints to a degree that may be reasonable in other settings may put patients at increased risk for complications in the COVID‐19 era, and tighter regulation of the WBC is a worthwhile consideration. This has to be carefully balanced with the potential need for additional blood draws and clinic visits, including blood product transfusions for worsening cytopenias. In a clinically suspected case of SARS‐CoV‐2 in an MDS/MPN patient, frequent monitoring of CBC, with use of additional doses of hydroxyurea to control an evolving leukemoid reaction may be beneficial, though this is unclear. The use of corticosteroids as antinflammatory agents is somewhat controversial, given concerns of potentially increasing ACE‐2 expression and viral replication/decreasing viral clearance, and should be used with caution. In the event of CRS or ARDS, treating physicians should consider potential early access to clinical trials or off‐label use of anti‐IL‐6 therapies (Table [1](#ajh25853-tbl-0001){ref-type="table"}). This recommendation is of particular importance in CMML, given that *TET2,* which is the most frequently mutated gene in CMML (60%), encodes a protein involved in the negative regulation of *IL6* gene expression. This suggests that *TET2*‐mutant patients may not be able to down‐regulate IL‐6 once the inflammatory cascade has been initiated.[^12^](#ajh25853-bib-0012){ref-type="ref"}

IL‐6 signals through three pathways: (a) cis signaling in immune cells, where it binds to membrane‐bound IL‐6‐R in a complex with gp30 and activates JAK‐STAT3, (b) trans signaling, where IL‐6 binds to soluble IL‐6‐R and then forms a complex with gp130 on potentially all cell surfaces, especially the endothelium, activating JAK‐STAT3 (cytokine storm and endothelial dysfunction), and (c) trans presentation, where IL‐6‐R binds to gp130 on T‐helper cells (Th17) leading to accentuated T cell signaling.[^13^](#ajh25853-bib-0013){ref-type="ref"} Current evidence points towards IL‐6‐R antagonists' being superior to IL‐6 neutralizing antibodies, due to the ability of the former in blocking trans presentation of IL‐6, an important mechanism in the development of acute lung injury and ARDS.[^13^](#ajh25853-bib-0013){ref-type="ref"} Preliminary data from China in SARS‐CoV‐2 with tocilizumab seems encouraging, with oxygen requirements being reduced in 75% of tocilizumab‐treated patients (n = 21). Clinical trials with sarilumab and siltuximab continue to accrue.

Given the inherent hypersensitivity of CMML cells to GM‐CSF (granulocyte macrophage), additional anti‐cytokine therapy using anti‐GM‐CSF monoclonal antibodies such as lenzilumab may also be considered. Of note, lenzilumab has been shown to abrogate neurotoxicity and CRS by neutralizing GM‐CSF in chimeric antigen receptor T‐cell mice models.[^14^](#ajh25853-bib-0014){ref-type="ref"} In addition, a recent phase 1 study of lenzilumab in CMML demonstated clinical benefit in 27% of patients, without any drug‐related grade 3 or 4 adverse events.[^10^](#ajh25853-bib-0010){ref-type="ref"} Mavrilimumab, a GM‐CSF receptor alpha directed mononclonal antibody is also being considered for the management of CRS in SARS‐CoV‐2. Additional cytokine‐directed clinical trials that might have value in the context of SARS‐CoV‐2 induced CRS include studies with anakinra (IL‐1beta receptor antagonist), empalumab (monoclonal antibody to interferon gamma, currently approved for HLH) and JAK inhibitors (ruxolitinib, pacritinib) (Table [1](#ajh25853-tbl-0001){ref-type="table"}). We continue to closely watch these studies for safety and efficacy signals. We recommend that all providers consider documenting any patients with hematological malignancies infected with SARS‐CoV‐2 in the American Society of Hematology (<http://www.ashresearchcollaborative.org/covid-19-registry>) and COVID19 and Cancer Consortium (CCC19 <http://ccc19.org>) registries.
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###### 

**Data S1**: Supporting information references.

###### 

Click here for additional data file.

###### 

**Figure S1** CMML patients are at even higher risk of a hyper‐inflammatory reaction and CYTOKINE STORM. CMML cells exhibit GM‐CSF hypersensitivity which pre‐primes the environment for inflammatory respossnse. Background concentrations of pro‐inflammatory cytokins (IL‐6, IL‐10, IL‐1b, TNF‐α) are increased in CMML patients compared with healthy controls. IL‐6, interleukin 6; IL‐8, interleukin 8; IL‐10, interleukin 10; IL‐1b, interleukin 1 beta; TNF‐α, tumor necrosis factor alpha; GM‐CSF, granulocyte‐macrophage colony‐stimulating factor.

###### 

Click here for additional data file.
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